SOURCE: Streetwise Reports

Streetwise Reports

April 21, 2016 09:00 ET

Relmada Therapeutics' Michael Becker Interviewed by The Life Sciences Report

SAN FRANCISCO, CA--(Marketwired - April 21, 2016) -  To treat chronic pain without risk of addiction is to straddle a knife's edge. But Relmada Therapeutics Inc. (OTCQB: RLMD) has a small fleet of compounds in development that address both sides of an issue that has become a newsmaker, given the recent upsurge in heroin addiction and the ever-present conundrum of alleviating severe pain in chronic disease and after surgery. In this interview with The Life Sciences Report, Relmada's Michael Becker describes the company's programs, which are advancing steadily toward the marketplace.

The Life Sciences Report: Relmada Therapeutics Inc. started out as a privately held company, but then completed a reverse merger and went public. Can you provide a bit of background on that process, and tell us the meaning behind the company's name?

Michael Becker: In May 2014, Relmada completed a reverse merger and listed on the OTCQB at $7.50 per share. In connection with the going-public transaction and subsequent warrant exercises, Relmada raised approximately $51 million in aggregate. With regard to the background behind the company's name, Relmada is an amalgamation of the phrase "relief armada," as the company is developing a pipeline of drug candidates to treat chronic pain.

TLSR: Let's talk about your new chemical entity, d-Methadone (dextromethadone; REL-1017), which is being developed for the treatment of neuropathic pain. Readers are familiar with traditional racemic methadone that is used in the treatment of various pain states and as a substitution therapy in heroin and other opioid addiction. How is your d-Methadone different?

MB: It is important to note that d-Methadone acts completely different from racemic methadone. As a single isomer of racemic methadone, d-Methadone has been shown to possess NMDA antagonist properties with virtually no opioid activity associated with the racemic molecule, or the l-Methadone isomer, at the expected therapeutic doses. The activation of NMDA receptors has been associated with…

Continue reading this interview: Relmada Therapeutics Launches Pharmaceutical Armada Against Chronic Pain and Opioid Abuse

About Streetwise Reports - The Life Sciences Report

Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. Our exclusive interviews with leading industry experts and analysts provide a clear picture of the causes of macro-economic shifts and the strategies that help you capitalize on developing trends.

Relmada Therapeutics Inc. paid Streetwise Reports to produce and distribute this interview. Relmada Therapeutics had final approval of the content and is wholly responsible for the validity of the statements. Opinions expressed are the opinions of Relmada Therapeutics and not of Streetwise Reports or its officers. The interview does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility.

Please see Streetwise Reports' terms of use and full legal disclaimer.

Contact Information